Indian health-tech pioneer develops the world’s first digital vaccine candidate for COVID-19 – ET HealthWorld

New Delhi [India] July 31 (ANI/Digpu): In the worldwide race towards time for a COVID-19 vaccine, this could possibly be a game-changing scientific breakthrough. Indian serial entrepreneur and investor, Bhargav Sri Prakash, Founder & CEO of well being tech pioneer, FriendsLearn have expanded a longstanding partnership with knowledge scientists and AI researchers on the Heinz College of Information Systems and Public Policy at Carnegie Mellon University (Pittsburgh, USA) to undertake a proposed population health human trial with a Digital Vaccine candidate (FYA-003) for COVID-19.

This initiative is led by healthcare informatics and analytics professional within the discipline, Prof Rema Padman and her workforce, via revolutionary extensions of the Digital Vaccine Project.

Digital vaccines have been described as a brand new frontier of illness prevention via expertise that allows neuro-behaviour and physiological modulation to guard well being at a person and societal scale. Carnegie Mellon University featured digital vaccines as a prime breakthrough in expertise as a part of their 12 months in overview annual publication, which is particularly noteworthy, provided that Carnegie Mellon University is the birthplace of Artificial Intelligence.

After almost a decade of basic neuroscience discoveries and translational scientific analysis in using AI and mobile-VR applied sciences, digital vaccines emerge with huge potential to disrupt the world of medication, via a give attention to precision prevention vs precision drugs.

FriendsLearn already delivers non-invasive, low-risk, and clinically-proven digital vaccine expertise via a commercially out there, subscription-driven, game-like, cell App known as FOOYA! for kids to obtain on iOS/Android/PCs. The app can also be out there via choose companion faculties in India.

Based on revealed outcomes from 4 pilot, cross-sectional scientific trials carried out with over 1000 youngsters, researchers discovered that youngsters who use FOOYA! make more healthy meals decisions in the true world.

A latest publication within the journal of global health promotion by unbiased researchers featured FOOYA! as a part of a scientific overview – thought-about the gold customary in evidence-based drugs – and concluded that the game-like expertise of FOOYA! resulted in higher engagement from youngsters.

Results from a dose-effect randomized managed trial undertaken by researchers at Carnegie Mellon University, Bloomberg School of Public Health at Johns Hopkins University and Hofstra University, confirmed optimistic and statistically important outcomes, which have been offered through the JMIR Connected Health Conference in Boston, USA.

FYA-003, a digital vaccine candidate for Covid-19, is a repurposed variant of the present digital vaccine platform. “We are re-purposing the mechanisms and technology from FOOYA! to help fight the global Covid-19 pandemic,” stated Sri Prakash.

“The technology has been developed and population-scale human trials are being planned soon, after which relevant scientific, ethical and regulatory approvals can be secured. By leveraging the FOOYA! the scientific evidence base, we aim for another drug-free and non-invasive digital vaccine that can save lives, without one having to inject or ingest anything that may have long term undesirable side effects,” added Sri Prakash.

Like FOOYA! FYA-003 will give attention to neuromodulation and neurocognitive coaching via immersive digital actuality to induce neuro-behavior-physiological change via the gut-brain axis and the physique’s immune system. Unlike FOOYA! which was focused at youngsters, FYA-003 is envisioned extra broadly for a wider age group.

“FOOYA! has already demonstrated promising evidence for science-based digital vaccine innovation that is targeted towards lowering the risk of lifestyle-related disease among children. We are currently in the process of adapting and scaling the existing platform towards supporting large scale, longitudinal, randomized field trials and conducting ongoing R&D to gather and analyze evidence of a variety of critical outcomes of interest to individuals and society. Global adoption of a digital vaccine for infectious diseases has the potential to help alleviate current health challenges caused by COVID-19, as well as for other infectious diseases in the future,” stated Prof Rema Padman of Carnegie Mellon University.

Accredited college well being companions which are already utilizing the FOOYA! App-based youngster well being safety platform will likely be preferentially eligible to take part on this ongoing analysis collaboration with the Digital Vaccine Project at Carnegie Mellon University, for validation of FYA-003.

This story is offered by Digpu. won’t be accountable in any method for the content material of this text. (ANI/Digpu)

LEAVE A REPLY

Please enter your comment!
Please enter your name here